On February 8th, Medexus Pharmaceuticals, a Canadian-based specialty pharma company, will release its quarterly financials. Why is this a big deal? Well, the company, serving both Canada and the US, is selling more than its market value. How crazy is that?

In this episode of Investor’s Roundtable, the crew at Equity Guru dig in Medexus and lay out its revenue model and how there is a complete disconnect between market valuation and the business the company is currently doing, never mind the growth potential and possible portfolio additions. Should you be putting Medexus on your investment radar? Tune in and find out for yourself.

Enjoy!